Welcome back from fishing...hope you did well.
Thanks for the compliment (I think?) I wouldn't consider myself a negative thinker, more pragmatic and cynical than most to be sure...
One question that immediately begs asking is "why did LIV wait two years to PR the pre-clin data for their cholesterol candidate?" I admittedly didn't research the archives to see whether this is a repeat release, but it seems odd to sit on that news, especially considering that it pre-dates the Phase II study results. Seems like momentum could have been developed a lot sooner.
The other question that I'm curious about is "how do they plan on completing an IND submission based on only one pre-clin study within 30 days?
Lastly, I'm curious as to what niche in the market they are trying to reach with this cholesterol candidate -- the market has numerous products in very late stage development that already show great results with minimum risk. LIV's drug is a minimum three years away. How do they prove to the street that their product is:
(a) Effective enough to bring to term, be it a partnership or an II investing in LIV
(b) Going to bring any return on investment
Here's a few questions that immediately come to mind. I'd be curious to find out what answers they provide.
Cheers...
Market Data 
Markets 
